In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onyx’s Transformative Year: From Productive Partner To Big Cap Contender?

Executive Summary

Onyx Pharmaceuticals is working to execute on two launches and produce late-stage data that will enable it to add more indications to its growing roster of marketed drugs. If it succeeds, it could eventually rival competitor Celgene as one of the few biotechs to move from a small cap into the big cap ranks, but any stumbles could slow or eliminate Onyx’s evolution.

Advertisement

Related Content

After ASH, Amgen Assuages Wall Street Over Kyprolis CV Concerns
As Onyx Details Come Out, Amgen Turns To Biosimilars
Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?
Amgen’s $125 Per Share Offer For Onyx Reflects Kyprolis Uncertainty
With Kyprolis Advancing, Millennium Stakes Faith In Oral Velcade Successor
Hang Onto The Launch: Investor Outlook Is Brighter For Some Biotechs
Hang Onto The Launch: Investor Outlook Is Brighter For Some Biotechs
How Kyprolis Overcame Serious Safety Fears To Reach Myeloma Market With Clean Label
Onyx Kyprolis Launch Strategy Includes Speedy Delivery, Premium Price
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel